Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

CNAO National Center of Oncological Hadrontherapy clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Italy register with CNAO National Center of Oncological Hadrontherapy as lead sponsor. Synced 16 Nov 2026
6Current trials
6Recruiting now
0Drugs in these trials
1Trial register
At a glance

CNAO National Center of Oncological Hadrontherapy is the lead sponsor of 6 current clinical trials in our Italy register. 6 are recruiting patients now. The most common phase is Not applicable. The most-studied condition is Head and Neck Cancer.

ClinicalTrials.gov trials by status

  • Recruiting6100%

Trials by phase

  • Not applicable350%
  • Observational350%
01

Clinical trials sponsored by CNAO National Center of Oncological Hadrontherapy

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Simultaneous Integrated Boost in Carbon Ion Radiotherapy for Head and Neck Adenoid Cystic Carcinoma
NCT05733910 · ClinicalTrials.gov ↗ · Carcinoma, Adenoid Cystic, Head and Neck Cancer
Not applicable Recruiting 2023-11 Italy
Innovative SolutIons for DosimEtry in Hadrontherapy (INSIDE)
NCT03662373 · ClinicalTrials.gov ↗ · Particle Therapy
Observational Recruiting 2019-07 Italy
Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract
NCT05478876 · ClinicalTrials.gov ↗ · Malignant Melanoma, Gynecologic Cancer
Not applicable Recruiting 2020-09 Italy
Longitudinal Registry Including Patients Treated With Heavy Particles
NCT05203250 · ClinicalTrials.gov ↗ · Cancer, Oncology, Radiation Exposure
Observational Recruiting 2021-06 Italy
HRQoL in Patients With Solid Tumors Treated With Hadrontherapy
NCT05947149 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Skull Base--Cancer, Brain Cancer
Observational Recruiting 2023-03 Italy
Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies
NCT05457595 · ClinicalTrials.gov ↗ · Tumor Recurrence, Malignant Epithelial Neoplasm of Vulva, Malignant Epithelial Tumor of Ovary
Not applicable Recruiting 2021-02 Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in CNAO National Center of Oncological Hadrontherapy trials

15 conditions
Head and Neck Cancer2Carcinoma, Adenoid Cystic1Particle Therapy1Malignant Melanoma1Gynecologic Cancer1Cancer1Oncology1Radiation Exposure1Radiotherapy Side Effect1Skull Base--Cancer1Brain Cancer1Tumor Recurrence1Malignant Epithelial Neoplasm of Vulva1Malignant Epithelial Tumor of Ovary1Malignant Epithelial Neoplasm1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in Italy66

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Head and Neck Cancer

SponsorTrials
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University5
Erasmus Medical Center3
ALX Oncology2
Varian, a Siemens Healthineers Company2
TScan Therapeutics2
Radiation Therapy Oncology Group2
University of Erlangen-Nürnberg Medical School2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2
Institut Claudius Regaud2
Centre Paul Strauss2

Sponsors with the most current trials registered for this condition.

05

Questions about CNAO National Center of Oncological Hadrontherapy trials

How many clinical trials does CNAO National Center of Oncological Hadrontherapy sponsor?

CNAO National Center of Oncological Hadrontherapy is the lead sponsor of 6 current trials on ClinicalTrials.gov in our Italy register, as of the registry sync on 16 November 2026. Completed and withdrawn studies are not counted.

Are CNAO National Center of Oncological Hadrontherapy trials recruiting?

Yes. 6 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 16 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.